Aura Biosciences, Inc. (AURA) Dividend History

Company News

• Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

  Aura Biosciences announced the pricing of a public offering of common stock and warrants, raising $75 million. The company plans to use the proceeds to advance its clinical programs in various cancer indications.

  Benzinga
• Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

  Aura Biosciences, a clinical-stage biotechnology company, announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to its Board of Directors. Bitetti's extensive operational and commercial experience will be valuable as Aura advances its clinical pipeline in ocular and urologic oncology.

  GlobeNewswire Inc.
• Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

  Aura Biosciences announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of non-muscle invasive bladder cancer will be presented at the European Association of Urology Congress. The company will also host a virtual investor event to discuss the data and provide a program update.

  GlobeNewswire Inc.
• 3 Small-Cap Stocks Ready to Deliver Significant Growth

  The article discusses three small-cap stocks that are poised for significant growth due to the Federal Reserve's recent interest rate cuts, which are expected to benefit small-cap companies that rely heavily on debt to fuel their growth.

  Benzinga

  Featured Companies: FBRT TZOO
• UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale

  By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.

  Zacks Investment Research

  Featured Companies: AMED ELV UNH